If rheumatoid arthritis (RA) patients don't respond to tumor necrosis factor (TNF) inhibitors, they have few options for alternative treatments.
If rheumatoid arthritis (RA) patients don't respond to tumor necrosis factor (TNF) inhibitors, they have few options for alternative treatments.
A company called Selventa may have a test to identify patients who won't respond to therapies, but there are few approved options for RA beyond TNF-targeting blockbusters from Amgen,...
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
The UK major's asthma drug gets a key expanded approval.
